Associate Professor
Dermatology
David Dicaudo practices Dermatology. He attended Northeast Ohio Medical University. He received 8 awards: "Top Doctors:Arizona State", "Teacher of the Year - Department of Dermatology", "Top Doctors", "Alpha Omega Alpha", "Harold O. Perry, MD Scholastic Achievement Award - Department of Dermatology", "Academic Scholarship", "Fellow (FAAD)" and "Super Doctor". David J. Dicaudo is a published physician. He published 41 publications, including: 'Clinical and histologic spectrum of human T-cell lymphotropic virus type I-associated lymphoma involving the skin.' Doctor David J. Dicaudo, MD is registered with Medicare and accepts Medicare payments.
Publications
Schools
Northeastern Ohio Universities College Of Medicine
Mayo Clinic Rochester
Procedures Preformed
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
Conditions Treated
- Acne
- Actinic Keratosis
- Basal Cell Carcinoma
- Benign Skin Lesion
- View All
Doctors Specialties
- Dermatopathology
- Dermatology
Accepted Insurances
Awards
- Top Doctors:Arizona State
- Teacher of the Year - Department of Dermatology
- Top Doctors
- Alpha Omega Alpha
- Harold O. Perry, MD Scholastic Achievement Award - Department of Dermatology
- Academic Scholarship
- Fellow (FAAD)
- Super Doctor
Education
-
Mayo School of Graduate Medical Education
-
Northeast Ohio Medical University
Hospital
-
Mayo Clinic - Rochester, Minnesota
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
NPI NUMBER |
|
1528040383 |
NPPES Provider LastName |
|
DICAUDO |
NPPES Provider FirstName |
|
DAVID |
NPPES Provider ZIPCode |
|
852595404 |
NPPES Provider State |
|
AZ |
Specialty Description |
|
Dermatology |
Total Claim Count |
|
29.0 |
Distinct Opioid Count |
|
0.0 |
Opioid Claim Count |
|
0.0 |
Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
National Provider Identifier [NPI] |
1528040383 |
Last Name Of The Provider |
DICAUDO |
First Name Of The Provider |
DAVID |
View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog